Adalimumab-atto Subcutaneous and Asenapine Maleate

• Generic Name: adalimumab
• Dosage Forms: n.a.
• Other Brand Names: Humira, Humira Pen, Humira Pen Crohns/UlcerColit/HidraSuppur, Humira Pen Psoriasis/Uveitis Starter Package, Humira Pediatric, Humira Pediatric Crohn's Disease Starter Pack, Humira Pre-Filled Syringe, Humira Pen Psoriasis/Uveitis/Adol HidraSuppur Starter Pack, Humira Pen Crohns/Ulcer Colitis/Hidradenitis Suppurati StrPk

Adalimumab-atto injection is used to treat the symptoms and prevent the progression of moderate to severely active rheumatoid arthritis and ankylosing spondylitis. It is used in children 4 years of age and older for juvenile idiopathic arthritis. Adalimumab-atto is also used to treat psoriatic arthritis, which is a type of arthritis that causes pain and swelling in the joints along with patches of scaly skin on some areas of the body. Psoriatic arthritis usually occurs with a skin condition called psoriasis. Adalimumab-atto may be used alone or in combination with medicines (eg, methotrexate).

Adalimumab-atto injection is also used to treat the symptoms of active Crohn’s disease in patients who have not been helped by other medicines (eg, infliximab). It is also used to treat moderate to severe ulcerative colitis in patients who have been treated with other medicines (eg, azathioprine, corticosteroids, or 6-mercaptopurine) that did not work well. Adalimumab-atto may also be used to treat moderate to severe chronic plaque psoriasis, which is a skin disease with red patches and white scales that don’t go away.

Adalimumab-atto is available only with your doctor’s prescription.

• Generic Name: asenapine
• Dosage Forms: n.a.
• Other Brand Names: Saphris, Saphris Black Cherry

Acute and maintenance treatment of schizophrenia in adults.

American Psychiatric Association (APA) considers most atypical antipsychotic agents first-line drugs for management of the acute phase of schizophrenia (including first psychotic episodes).

Patients who do not respond to or tolerate one drug may be successfully treated with an agent from a different class or with a different adverse effect profile.

Acute treatment as monotherapy or adjunctive therapy with lithium or valproate of manic or mixed episodes associated with bipolar I disorder (with or without psychotic features).

Maintenance treatment as monotherapy of bipolar I disorder.